In:
European Journal of Haematology, Wiley, Vol. 110, No. 4 ( 2023-04), p. 379-385
Abstract:
To elucidate the clinical characteristics of AA patients with cytogenetic abnormalities. Methods We retrospectively screened 30 patients (30/1206, 2.5%) with cytogenetic abnormalities from 1206 patients with severe and very severe AA who received immunosuppressive therapy (IST) during the years 2012–2019. Results The most common abnormalities were trisomy 8 (+8, 10/30, 33.3%) and loss of Y (−Y, 8/30, 26.7%). The abnormal clones disappeared 6 months after IST in 14 patients and sustained in 12 patients. Patients with sustained abnormal clones had a lower hematologic response at 6 months after IST than the disappeared (33.3% vs. 64.3%, p = .116). The hematologic response after IST, 5‐year overall survival, 5‐year event‐free survival, myelodysplastic syndrome or acute myeloid leukemia transformation in AA patients with cytogenetic abnormalities were not statistically different from those in normal cytogenetic patients. Conclusion For AA patients with chromosome abnormalities but ineligible for hematopoietic stem cell transplant, IST is effective and appropriate as first‐line treatment.
Type of Medium:
Online Resource
ISSN:
0902-4441
,
1600-0609
Language:
English
Publisher:
Wiley
Publication Date:
2023
detail.hit.zdb_id:
2027114-1
Bookmarklink